TY - JOUR
T1 - Large outbreak of neisseria meningitidis Serogroup C — Nigeria, December 2016–June 2017
AU - Nnadi, Chimeremma
AU - Oladejo, John
AU - Yennan, Sebastian
AU - Ogunleye, Adesola
AU - Agbai, Chidinma
AU - Bakare, Lawal
AU - Abdulaziz, Mohammed
AU - Mohammed, Amina
AU - Stephens, Mary
AU - Sumaili, Kyadindi
AU - Ronveaux, Olivier
AU - Maguire, Helen
AU - Karch, Debra
AU - Dalhat, Mahmood
AU - Antonio, Martin
AU - Bita, Andre
AU - Okudo, Ifeanyi
AU - Nguku, Patrick
AU - Novak, Ryan
AU - Bolu, Omotayo
AU - Shuaib, Faisal
AU - Ihekweazu, Chikwe
N1 - Publisher Copyright:
© 2017, Department of Health and Human Services. All rights reserved.
PY - 2017/12/15
Y1 - 2017/12/15
N2 - What is already known about this topic? Meningococcal disease caused by Neisseria meningitidis causes severe illness, and could lead to permanent disability or death if not quickly detected and treated. The largest global burden of meningococcal disease is in sub-Saharan Africa, where annual epidemics caused mainly by N. meningitidis serogroup A were previously common. After the introduction of meningococcal A vaccines in 2013, meningitis caused by serogroup A declined. However, N. meningitidis serogroup C (NmC) has now emerged as a cause of large outbreaks. What is added by this report? During December 2016–June 2017, the largest global epidemic of meningitis caused by NmC occurred in northern Nigeria, with 14,518 suspected cases and 1,166 deaths reported. An emergency operations center coordinated rapid development and implementation of an emergency outbreak response plan, including administration of meningococcal serogroup C– containing vaccines to >2 million persons. Multiple logistical challenges were encountered during the response; the outbreak was declared over in June 2017. What are the implications for public health practice? National and regional evaluations of the outbreak response have outlined recommendations for improving meningitis outbreak prevention, timely detection, and response in Nigeria. Implementation of these recommendations will be key to reducing future meningitis outbreaks. Expanding availability of multivalent vaccines that are effective against non-A serogroups of N. meningitidis might prevent future outbreaks in this region.
AB - What is already known about this topic? Meningococcal disease caused by Neisseria meningitidis causes severe illness, and could lead to permanent disability or death if not quickly detected and treated. The largest global burden of meningococcal disease is in sub-Saharan Africa, where annual epidemics caused mainly by N. meningitidis serogroup A were previously common. After the introduction of meningococcal A vaccines in 2013, meningitis caused by serogroup A declined. However, N. meningitidis serogroup C (NmC) has now emerged as a cause of large outbreaks. What is added by this report? During December 2016–June 2017, the largest global epidemic of meningitis caused by NmC occurred in northern Nigeria, with 14,518 suspected cases and 1,166 deaths reported. An emergency operations center coordinated rapid development and implementation of an emergency outbreak response plan, including administration of meningococcal serogroup C– containing vaccines to >2 million persons. Multiple logistical challenges were encountered during the response; the outbreak was declared over in June 2017. What are the implications for public health practice? National and regional evaluations of the outbreak response have outlined recommendations for improving meningitis outbreak prevention, timely detection, and response in Nigeria. Implementation of these recommendations will be key to reducing future meningitis outbreaks. Expanding availability of multivalent vaccines that are effective against non-A serogroups of N. meningitidis might prevent future outbreaks in this region.
UR - http://www.scopus.com/inward/record.url?scp=85038369997&partnerID=8YFLogxK
U2 - 10.15585/mmwr.mm6649a3
DO - 10.15585/mmwr.mm6649a3
M3 - Article
C2 - 29240724
AN - SCOPUS:85038369997
SN - 0149-2195
VL - 66
SP - 1352
EP - 1356
JO - Morbidity and Mortality Weekly Report
JF - Morbidity and Mortality Weekly Report
IS - 49
ER -